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Infection by Epstein-Barr virus (EBV) generates several types of latency with different profiles of gene
expression but with expression of Epstein-Barr nuclear antigen 1 (EBNA-1) in common. The BamHI Q
promoter (Qp) is used for the transcription of EBNA-1 mRNA in type I latency, which is an EBV infection state
exemplified by Burkitt’s lymphoma (BL). However, Qp is inactive in type III latency, and other promoters
(C/Wp) are used for transcription of EBNA-1, which raises the question of how usage of these promoters is
governed. Interferon (IFN) regulatory factor 7 (IRF-7) was identified first as a negative regulator of Qp.
Expression of IRF-7 is associated with EBV type III latency, where Qp is inactive, but not with type I latency,
raising the possibility that a viral gene product(s) expressed in type III latency might induce IRF-7 and repress
Qp. Here, detailed analysis of the expression of IRF-7 revealed that it is associated with the expression of EBV
latent membrane protein 1 (LMP-1) and that LMP-1 stimulates the expression of IRF-7 in type III latency in
which Qp is inactive. In contrast, LMP-1 is not expressed in type I latency cells in which Qp is active. LMP-1
represses the constitutive activity of Qp reporter constructs. Mutational analysis of Qp reporter constructs
revealed that the Qp IFN-stimulated response element (ISRE) is essential for the repression by LMP-1.
Furthermore, LMP-1 reduced EBNA-1 mRNA derived from Qp only in type I cells in which IRF-7 could be
induced. Finally, IFN-␣, but not IFN-␥, repressed endogenous Qp activity, which is consistent with the ability
of IFN-␣ to induce IRF-7. Thus, IRF-7 may mediate repression of Qp by LMP-1. The induction of IRF-7 by
LMP-1 may be relevant to the silencing of Qp in EBV type III latency.
I latency, the BamHI Q promoter (Qp) is used for the transcription of EBNA-1 mRNA. However, in type III latency, Qp
is silent, and the BamHI C and/or BamHI W promoters (C/
Wp) are used. The biological consequence of the Qp-to-C/Wp
switch and the conversion to type III latency is the expression
of the full spectrum of latency genes (reviewed in references 25
and 43), which confers enhanced cell survival, growth, and
invasive potential (8, 17, 19, 22, 53, 60, 65).
Since Qp usage not only relates to the survival of the virus in
an immunocompetent host but also is associated with several
tumors, dissecting the regulation of Qp is essential for understanding the viral program in EBV-associated malignancies.
The functional importance of Qp for the EBV life cycle is
underscored by the facts that all EBV-positive tumor specimens collected from Africa, North America, and Asia have
conserved Qp sequence (58) and that conserved structural and
functional cis elements (e.g., an interferon [IFN]-stimulated
response element [ISRE] and the Q locus [see Fig. 4A]) also
exist in the Old World primate lymphocryptoviruses, which are
simian EBVs (47). Both EBNA-1 and host factors are involved
in the transcriptional regulation of Qp. The downstream element of Qp, the Q locus (Fig. 4A), contains two binding sites
for the EBNA-1 protein, which binds to and acts in an autoregulatory manner to repress Qp transcription (48, 56). However, E2F-1 overcomes EBNA-1-mediated repression of Qp in
transient transfection assays, and E2F-1 binds to the Q locus
and displaces the binding of EBNA-1 (55), so that the promoter is regulated in a cell cycle-dependent manner (10).
An ISRE immediately upstream of the transcriptional initiation site has been discovered and appears to be essential for
Qp constitutive activity (39, 49, 56, 67). IFN regulatory factors
(IRFs), which are a group of transcription factors with multiple
functions (reviewed in reference 37), have the potential to bind
to the Qp ISRE and to regulate the activity of Qp. Although

The biologic hallmark of Epstein-Barr virus (EBV) and its
usual interaction with B lymphocytes is latency. Several types
of latency with distinct patterns of viral gene expression have
been described. Type I latency is exemplified by Burkitt’s lymphomas (BL) in vivo and earlier passages of cultured cell lines
derived from BL tissues. EBV nuclear antigen 1 (EBNA-1),
and in some cases latent membrane protein 2A (LMP-2A), is
expressed in this form of latency (7, 35, 36, 41, 59). Several
reports suggest that a type I-like form of latency exists in
healthy carriers of EBV (7, 35, 36, 41, 59). Interestingly, cells
in type I latency can escape host immune surveillance because
EBNA-1 can interfere with its peptide presentation on major
histocompatibility complex class I molecules (29), which might
explain the lifelong reservoir of virus in immunocompetent,
seropositive persons. Type III latency is represented by lymphoblastoid cell lines established after EBV infection of adult
primary B cells in vitro, by some BL lines, and in B-cell lymphomas in immunodeficient states. Nine viral proteins, including six nuclear proteins (EBNA-1, EBNA-2, EBNA-3A,
EBNA-3B, EBNA-3C, and EBNA-LP) and three integral
membrane proteins (LMP-1, LMP-2A, and LMP-2B), are expressed. In addition, in all three forms of latency, EBV-encoded RNAs (EBERs) are expressed (reviewed in references
25 and 43).
EBNA-1 is the sole viral protein needed for the replication
of the EBV episome and maintenance of the latent infection
state; both events are essential for cell immortalization (reviewed in references 25 and 43). The promoter usage for expression of EBNA-1 differs in different types of latency. In type
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the major positive regulator of Qp through the ISRE is disputed (39, 49, 68), both IRF-2 and the newly identified IRF-7
have been reported to be negative regulators of Qp (67, 68).
IRF-7 is predominately expressed in lymphoid tissues, and four
splicing forms (IRF-7A, IRF-7B, IRF-7C, and IRF-7H) have
been identified (4, 67). IRF-7A is apparently the major form of
IRF-7 in peripheral blood leukocytes (67).
LMP-1 can induce a variety of cellular genes and enhance
cell survival, adhesion, and invasive potential (13, 22, 34, 62,
63, 65). LMP-1 expression is also necessary for B-cell transformation by EBV. Here, we report that LMP-1 stimulates the
expression of IRF-7. Furthermore, LMP-1 can repress Qp activity. Because IRF-7 is a negative regulatory of Qp and LMP-1
is expressed in type III latency, induction of IRF-7 by LMP-1
may provide an indirect pathway for the silencing of Qp in type
III latency.
MATERIALS AND METHODS
Cell culture. DG75 is an EBV-negative BL cell line (5); BL30 and BL41 are
EBV-negative BL lines with EBV-infected counterparts generated by in vitro
infection with the P3HR1 strain (BL30-P3HR1 and BL41-P3HR1) or the B95-8
strain (BL30-B95-8 and BL41-B95-8) of EBV (6). Akata, Eli-BL (gift from Alan
Rickinson), and Rael (gift from Richard Ambinder) are all EBV-positive type I
BL cell lines (27, 45, 57). Jijoye and its derivative P3HR1 are EBV-positive type
III BL cell lines (2, 42). The stable cell lines expressing either LMP-1 or EBNA-2
in BJAB or BL41 cells were gifts from Fred Wang (63). All cell lines described
were maintained in RPMI 1640 plus 10% fetal bovine serum. Suitable selection
drugs were added to the stable cell lines as reported elsewhere (63).
Plasmids and antibodies. IRF-7A and EBNA-2 expression plasmids and
IRF-7 antibody have been described elsewhere (40, 54, 67). pcDNA/CD4 is a
human CD4 expression plasmid (gift from Jenny Ting). The ␤-galactosidase
expression plasmid, pCMV␤ (6177-1), was purchased from Clontech. pQ1-CAT
and pQ2-CAT are described elsewhere (68). The LMP-1 expression plasmid,
pcLMP-1, was a gift from Tomakazu Yoshizaki. pQ2M-CAT (⫺173 to ⫹5) was
made by cloning the corresponding PCR fragment with mutations in ISRE
sequence into pBS-CAT (14). The IRF-1 (C-20) and IRF-2 (C-19) antibodies
were purchased from Santa Cruz Biotechnology, Inc. The EBNA-2 monoclonal
antibody, PE-2, and LMP-1 monoclonal antibody, S12, were derived from their
respective hybridoma cell lines (31, 66). IFN-stimulated gene 15 (ISG-15) monoclonal antibody (11) was a gift from Ernest Borden.
Western blot analysis with enhanced chemiluminescence. Separation of proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was done according to standard methods. After the proteins were transferred to
a nitrocellulose or Immobilon membrane, the membrane was blocked with 5%
nonfat dry milk in TBST (50 mM Tris [pH 7.5], 200 mM NaCl, 0.05% Tween 20)
at room temperature for 10 min. It was then washed briefly with water and
incubated with a primary antibody in 5% milk in TBST for 1 to 2 h at room
temperature or overnight at 4°C. After being washed with TBST for 10 min three
times, the membrane was incubated with the secondary antibody at room temperature for 1 h. It was then washed three times with TBST as before, treated
with enhanced chemiluminescence (Amersham) or SuperSignal (Pierce) detection reagents, and exposed to Kodak XAR-5 film.
Transient transfection, CAT assays and isolation of transfected cells. For
DG75 and Akata cells, 107 cells in 0.5 ml of medium with 5 to 10 g of DNA were
used for transfection with the use of a Bio-Rad Gene Pulser (320 V and 925 F).
For Eli-BL cells, 50 g of DNA was used at 320 V and 975 F. Two days after
transfection, cells were collected for chloramphenicol acetyltransferase (CAT)
assay or for isolation of transfected cells. The CAT and ␤-galactosidase assays
were essentially the same as described elsewhere (16). The CAT assay results
were analyzed on a Molecular Dynamics PhosphorImager.
For isolation of transfected cells, cells were collected after transfection and
enrichment for CD4 positive cells was performed with the use of anti-CD4
antibody conjugated to magnetic beads as recommended by the manufacturer
(Dynal, Inc.). The isolated cells were used for the extraction of total RNA.
RNA extraction and RPA. Total RNA was isolated from cells with the use of
RNease total RNA isolation kit (Qiagen). RNase protection assays (RPA) was
performed with total RNA with the use of an RNase Protection Kit II (Ambion
Inc.). The hybridization temperature was 45°C. The glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe was supplied by U.S. Biochemicals, Inc. The
IRF-7 probe was generated with the use of ApaLI-digested pBS-IRF7A as a
template and T7 RNA polymerase. The protected region is nucleotides 1671 to
1890 of IRF-7A (67). This probe cannot distinguish various splicing forms of
IRF-7. The EBNA-1 probe was described previously (68). Molecular weight
markers were made with the use of a ␥-32P-labeled DNA marker, (ØX174
DNA/HinfI; Promega).
IFN. IFN-␣-2a was purchased from Hoffman La Roche Inc.; IFN-␥ was from
Genzyme. For IFN treatments, cells were treated with either IFN-␣ (500 U/ml)

FIG. 1. Association between the expression of IRF-7 and LMP-1. Equal
amounts of protein lysates from the indicated cell lines were separated by
SDS-PAGE (10% gel) and stained with Ponceau S red after transfer of protein
to the membrane. Western blotting with IRF-7, IRF-1, IRF-2, and LMP-1
antibodies was performed.

or IFN-␥ (500 U/ml) for 48 h and were collected for further analysis. The same
amounts of H2O or 1⫻ phosphate-buffered saline were used as mock treatments.

RESULTS
Expression of IRF-7 is associated with LMP-1 protein in
type III latency. We have shown that high levels of IRF-7 and
IRF-2 are associated with type III, but not type I, latency (67,
68), which raises the possibility that a viral gene(s) may regulate the expression of IRF-7 or IRF-2. Because only EBNA-1,
and possibly LMP-2A, is expressed in type I latency, but all of
the latency proteins (EBNA-1, -2, -3A, -3B, and -3C, and
LMP-1, -2A, and -2B) are expressed in type III latency, one or
more viral genes expressed in type III latency may be responsible for the upregulation of IRF-2 and IRF-7.
To select a candidate gene(s), paired cell lines infected by
EBV P3HR1 virus or the prototype B95-8 strain were examined. BL30-P3HR1 and BL30-B95-8 lines were established by
infecting the EBV-negative BL30 line with P3HR1 and B95-8
viruses, respectively. The BL41-P3HR1 and BL41-B95-8 lines
were established similarly (6). B95-8 virus has all of the latency
genes in its viral genome, whereas the P3HR1 virus genome
lacks the EBNA-2 gene and a portion of the EBNA-LP gene
(2). The cell lines infected with P3HR1 virus did not express
EBNA-2 and had a much lower level of LMP-1, whereas both
cell lines infected with B95-8 virus expressed high levels of
LMP-1 because EBNA-2 can transactivate the LMP-1 promoter (1, 15, 61, 64) (Fig. 1 and data not shown). The expression of IRFs in these lines was examined by Western blotting
with specific antibodies. IRF-7 was shown to be expressed at
high levels in the two cell lines infected with B95-8 virus, both
of which have a high level of LMP-1 (Fig. 1, lanes 3 and 6). The
levels of IRF-1 and IRF-2, on the other hand, did not correlate
with the high levels of LMP-1 expression. The IRF-1 level was
high in all cell lines tested. These experiments were repeated
several times, and consistent results were obtained. Furthermore, the type III Jijoye cell line, which has high-level expression of LMP-1 and is the parental line for P3HR1 cells, has a
higher level of IRF-7 than P3HR1 cells, which have a lower
LMP-1 level (data not shown).
These data strongly suggest that high-level expression of
IRF-7 in type III latency is associated with the expression of
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FIG. 2. LMP-1 increases levels of endogenous IRF-7 protein. Western blotting with IRF-7, IRF-2, LMP-1, and EBNA-2 antibodies was performed. Lanes
1 to 7, stable cell lines established from the EBV-negative BJAB cell line; lanes
3 and 4, LMP-1 expression lines (MTLM-6 and MTLM-18); lanes 6 and 7,
EBNA-2 expression lines (pZu2-4 and pZu2-5); lanes 1 and 2, vector control
lines for LMP-1 (gpt-1 and gpt-2); lane 5, vector control line for EBNA-2 (pZ-3);
lanes 8 and 9, LMP-1 expression line in BL41 (BL41-MTLM c11; lane 9) and its
control cell line (BL41-gpt-3; lane 8). n.s., nonspecific band in lane 5.

LMP-1. In contrast, an association of IRF-1 and IRF-2 with
EBV protein expression was not apparent.
LMP-1 stimulates the expression of IRF-7 protein. Since
there was a consistent association between high levels of
LMP-1 in type III latency and IRF-7, whether LMP-1 could
directly stimulate IRF-7 was examined in stable cell lines expressing either LMP-1 or EBNA-2 (Fig. 2). MMLM-6 and
MMLM-18 are EBV-negative BJAB lines expressing LMP-1
protein constitutively, whereas pZu2-4 and pZu2-5 express
EBNA-2 protein. pZ-3, gpt-1, and gpt-2 are vector control
lines for the EBNA-2 (pZ-3) and LMP-1 (gpt-1 and gpt-2)
lines (63). The expression of EBNA-2 and LMP-1 was confirmed by Western blot analysis with EBNA-2 or LMP-1 antibody. As shown in Fig. 2, expression of IRF-7 is higher in
LMP-1-expressing lines (lanes 3 and 4) than it is in the negative
control lines (lanes 1 and 2). However, IRF-2 was not affected
by LMP-1 expression. Neither the IRF-7 nor the IRF-2 level
was stimulated in the EBNA-2-expressing cell lines (lanes 5 to
7).
To address further whether LMP-1 could stimulate IRF-7,
we used BL41-MTLM c11, a BL41 line stably transfected with
an LMP-1 expression plasmid (63). As shown in Fig. 2, expression of IRF-7 is also higher in this LMP-1-expressing line than
in its control line, BL41-gpt-3 (lanes 8 and 9). These results
suggest that LMP-1, but not EBNA-2, can stimulate the expression of IRF-7 protein.
LMP-1 stimulates the expression of IRF-7 mRNA. Whether
LMP-1 can increase IRF-7 mRNA was examined by RPA with
a specific probe (see Materials and Methods for details). In a
pair of genetically identical lines, the IRF-7 mRNA level was
higher in the type III line (Sav III), where LMP-1 is expressed,
than in the type I line (Sav I), where there is no LMP-1
expression (Fig. 3, lanes 3 and 4). The difference in IRF-7
mRNA between the two lines is more than 10-fold (Fig. 3).
Also, the level of IRF-7 mRNA is low in Eli-BL, Akata, and
Rael cells (type I lines) but higher in Jijoye and CB95 cells
(type III lines) (data not shown). Therefore, IRF-7 mRNA
expression is also associated with type III latency, in agreement
with previous reports (39, 67).
Whether LMP-1 could increase IRF-7 mRNA was examined

FIG. 3. LMP-1 increases endogenous IRF-7 mRNA. (A) IRF-7 and GAPDH
probes were labeled with [␣-32P]UTP and used for RPA. Lanes 1 and 2, undigested IRF-7 and GAPDH probes; lanes 3 and 4, RNAs from Sav I and Sav III
cells, respectively; lane 5, yeast tRNA; lanes 6 to 11, RNAs from transfected and
concentrated DG75 cells; lanes 7 and 8, an LMP-1 expression plasmid was used
for transfection; lanes 10 and 11, EBNA-2 expression plasmid; lanes 6 and 9,
control vectors. Specific protection of IRF-7 and GAPDH mRNAs and undigested probes is indicated. (B) Short time exposure for GAPDH-protected areas.
The IRF-7 mRNA in Sav III was 10.4-fold ⫾ 1.9-fold higher than in Sav I. The
enhancement of IRF-7 mRNA by LMP-1 was 2.4-fold ⫾ 0.4-fold, whereas
enhancement by EBNA-2 was 0.63-fold ⫾ 0.2-fold. Data were obtained by
normalizing IRF-7 levels to the GAPDH level with the use of a PhosphorImager.

by transient transfection of LMP-1 and a CD4 expression plasmid into DG75 cells, which is an EBV-negative line, and selecting transfected cells by the use of anti-CD4 antibody-conjugated magnetic beads (see Materials and Methods for
details). As shown in Fig. 3, LMP-1 expression causes an increased level of IRF-7 mRNA (lanes 7 and 8) compared with
vector alone (lane 6). In contrast, EBNA-2 did not stimulate
the expression of IRF-7 mRNA (lanes 9 to 11). Western blot
analysis confirmed that IRF-7A protein was greater in amount
in LMP-1-transfected cells than in pcDNA3-transfected cells
(data not shown). The mRNA data are also consistent with
results from Western blot analyses of LMP-1- and EBNA-2expressing lines (Fig. 2). The data together suggest that LMP-1
stimulates the expression of IRF-7 mRNA.
LMP-1 represses the constitutive activity of Qp reporter
constructs. Because IRF-7 has been shown to be a negative
regulator of Qp (67, 68), the stimulation of IRF-7 by LMP-1
predicts that LMP-1 might act indirectly as a negative regulator
of Qp. To test this idea, an LMP-1 expression plasmid and a
Qp reporter construct were cotransfected into DG75 cells, and
CAT activity was assayed 2 days later, with ␤-galactosidase
activity as an internal transfection efficiency control. The
pQ2CAT construct was chosen to assay Qp activity because the
constitutive activity of pQ2CAT correlates with endogenous
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FIG. 4. Repression of Qp reporter constructs by LMP-1. (A) Schematic
diagram of Qp and Qp reporter constructs. Open rectangle, ISRE; solid bars,
E2F binding sites; ovals, EBNA-1 sites (Q locus). The RNA start site for Qp is
indicated by an arrow (50). The mutations in the Qp ISRE are shown. (B)
Repression of Qp by LMP-1 in B cells. DG75 cells were transfected with the
reporter construct pQ2-CAT along with the pcDNA-3 vector (column 1), with
0.2 and 0.4 g of LMP-1 expression plasmid pcLMP-1 (columns 2 and 3, respectively), with an EBNA-2 expression plasmid (column 5), or with pcDNA-IRF-7A
(column 6). (C) Mutations in ISRE abolish the repression of Qp by LMP-1 and
by IRF-7. DG75 cells were transfected with reporter construct pQ2M-CAT and
pcDNA-3 (column 1), pcLMP-1 (column 2), or pcDNA-IRF-7A (column 3). (D)
LMP-1 did not repress Qp reporter construct in Akata cells. Akata cells were
transfected with the reporter construct pQ2-CAT and with pcDNA-3 vector
(column 1) or with 0.2 and 0.4 g of LMP-1 expression plasmid pcLMP-1
(columns 2 and 3, respectively). CAT assay results were normalized by ␤-galactosidase activity. CAT activity is expressed relative to the vector control level.
Standard deviations are shown.

Qp activity and is more responsive to IRF-7 (68). As shown in
Fig. 4B, LMP-1 repressed activity of the Qp reporter construct
(columns 1 to 3). EBNA-2 protein expression did not repress
Qp (column 4), which is consistent with the fact that EBNA-2
does not induce IRF-7 (Fig. 2 and 3). Overexpression of IRF-7
repressed Qp as expected (column 5). Furthermore, mutations
in the ISRE of Qp (Fig. 4A) prevented the repression by

J. VIROL.

LMP-1 or by IRF-7A (Fig. 4C). It should be noted that ISRE
mutation greatly reduced the constitutive activity of Qp as
reported previously (39, 49, 56, 67).
It is interesting that we did not detect any stimulation of
IRF-7 expression after overexpression of LMP-1 in Akata cells
(Fig. 5B). Therefore, whether LMP-1 could repress Qp reporter constructs in these cells was tested. As shown in Fig. 4D,
LMP-1 failed to repress Qp in Akata cells. The Akata line is
unusual in that some LMP-1-inducible genes cannot be induced in these cells, and anti-human immunoglobulin G can
trigger lytic replication of EBV (46, 57). However, LMP-1
could activate NF-B in this line (data not shown).
Since high-level expression of LMP-1 has been reported to
have a toxic effect on some cells (12, 20), whether the reduction
in Qp constitutive activity by LMP-1 was due to toxicity was
examined carefully. First, there were no obvious differences in
␤-galatosidase activity with or without LMP-1. Second, an
NF-B reporter construct was activated with the expression of
LMP-1 as expected (data not shown and references 28 and 46).
Third, endogenous IRF-7 mRNA was enhanced by LMP-1 in
DG75 cells under the same transfection conditions (Fig. 3).
Therefore, the data suggest that LMP-1 can repress Qp activity, and the repression is associated with IRF-7 stimulation.
LMP-1 reduces endogenous EBNA-1 mRNA in type I latency
cells. To test if LMP-1 represses endogenous Qp activity, the
LMP-1 and CD4 expression plasmids were transfected into
Eli-BL, a type I cell line in which Qp is active. The RNA from
the transfected cells was isolated, and RPA with an EBNA-1specific probe was performed. The Eli-BL line was chosen
because LMP-1 could stimulate the expression of IRF-7 in this
line (Fig. 5B). As shown in Fig. 5A, LMP-1 indeed reduced the
level of EBNA-1 mRNA in Eli-BL cells (compare lanes 4 and
5 with lane 3). However, LMP-1 did not induce IRF-7 (Fig. 5B,
lane 6) or reduce EBNA-1 mRNA in Akata cells (Fig. 5A, lane
10). The EBNA-1 mRNA level in Akata cells is lower than it
is in Eli-BL cells, possibly because the EBV genome is lost in
subpopulations of Akata (52), resulting in differences in viral
genome copy numbers. The reduced level of EBNA-1 mRNA
produced in Eli-BL cells by LMP-1 is most likely due to the
repression of Qp activity, because LMP-1 could repress the
activity of Qp reporter constructs to a similar extent (Fig. 4B).
These data suggest that LMP-1 can repress the endogenous
activity of Qp, and the repression is associated with the ability
of LMP-1 to induce the expression of IRF-7.
Repression of Qp by IFN is associated with the induction of
IRF-7. Because IFN has been shown to induce the expression
of IRF-7 (4, 32, 39), whether IFN can repress endogenous Qp
was tested in the type I latency cells, Eli-BL and Rael; in both
cell lines, endogenous Qp is active. IFN-␣ could induce the
expression of IRF-7 in Eli-BL cells but not in the Rael cell line
(Fig. 6B, lanes 2 and 5). The reason that IFN-␣ fails to induce
IRF-7 in Rael cells is unknown; however, the signal transduction pathway for IFN-␣ in Rael cells is at least partially functional because the expression of ISG-15 could be greatly induced (Fig. 6C, lanes 2 and 3; reference 11). IFN-␥ could not
induce IRF-7 in either cell line (Fig. 6B, lanes 3 and 6), which
is consistent with a previous report (4). However, IFN-␥ could
enhance the expression of Tap-2 (transporter associated with
antigen processing 2), suggesting that IFN-␥ was functional as
reported (data not shown; references 30 and 44). Whether IFN
represses the endogenous Qp was addressed with the use of
RPA with an EBNA-1-specific probe. Figure 6A shows that
IFN-␣ indeed reduced the Qp-derived EBNA-1 mRNA in the
Eli-BL cells (lane 4). In contrast, IFN-␣ failed to repress Qp in
the Rael line, in which IFN-␣ did not induce the expression of
IRF-7 (Fig. 6A, lane 7). The reduced level of EBNA-1 mRNA
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FIG. 5. LMP-1 reduces the endogenous EBNA-1 mRNA transcribed from Qp in type I cells. (A) Reduction of endogenous EBNA-1 mRNA in cells transfected
with an LMP-1 expression plasmid. RPA was performed with GAPDH and EBNA-1 probes with various RNAs. Lane 1, yeast RNA; lane 2, total RNA from DG75,
an EBV-negative cell line; lanes 3 to 5, RNAs from Eli-BL cells transfected with pcDNA3, pcLMP1 (5 g), and pcLMP1 (10 g), respectively; lanes 6 and 7, RNAs
from Akata cells transfected with pcDNA3 and pcLMP1, respectively. The relative EBNA-1 mRNA levels are shown. Data were analyzed by normalizing EBNA-1
mRNA levels to the GAPDH level with the use of a PhosphorImager. In LMP-1-transfected cells, the average EBNA-1 mRNA level (and standard deviation) relative
to pcDNA3-transfected cells from four experiments was 0.52 ⫾ 0.09. One representative experiment is shown. (B) Stimulation of IRF-7 by LMP-1 in Eli-BL cells. RPA
was performed with GAPDH and IRF-7 probes with various RNAs. Lane 1, yeast RNA; lanes 2 to 4, RNAs from Eli-BL cells transfected with pcDNA3, pcLMP1 (5
g), and pcLMP1 (10 g), respectively; lanes 5 and 6, RNAs from Akata cells transfected with pcDNA3 and pcLMP1 respectively. One representative experiment is
shown.

in Eli-BL cells is most likely due to the repression of Qp
activity, because IFN-␣ could repress the activity of Qp reporter constructs (data not shown and reference 39). IFN-␥ did
not repress Qp in either cell line, as expected (Fig. 6A, lanes 5
and 8). These data suggest that IFN-␣ can repress the endogenous activity of Qp. This effect is associated with the ability of
IFN-␣ to induce the expression of IRF-7.
DISCUSSION
EBV can deregulate B-cell growth through activation of
endogenous programs of cellular gene expression. At the same
time, these deregulated cellular genes can modulate the program of viral gene expression. The switch from Qp to C/Wp
usage, which allows transcription of other EBNA proteins
(EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNA-LP),
produces a phenotypic conversion from type I to type III latency. We previously identified a novel regulator for Qp,
IRF-7, which is highly expressed in type III latency. In this
work, LMP-1, a key type III latency protein, is identified as an

inducer of IRF-7. First, IRF-7 is associated with type III latency, in which LMP-1 is expressed (67). Second, high levels of
IRF-7 are associated with LMP-1 expression in EBV-infected
BL-30 and BL-41 cell lines (Fig. 1). Third, stable expression of
LMP-1 in EBV-negative BJAB as well as BL41 cell lines increases the endogenous expression of IRF-7 protein (Fig. 2).
Fourth, transient transfection of LMP-1 into DG75 or Eli-BL
cells could increase the endogenous expression of IRF-7
mRNA (Fig. 3 and 5). Fifth, a physiological level of LMP-1
seems also able to stimulate IRF-7 mRNA expression (Fig. 3).
More work is needed to dissect the domains of LMP-1 required for induction of IRF-7.
Interestingly, it has been argued that the induction of bcl-2
by LMP-1 may be due to the selection of a cell population with
high endogenous expression of bcl-2 (33). Since transient expression of LMP-1 in DG75 or Eli-BL cells could stimulate the
expression of IRF-7, LMP-1 is more likely able to enhance
IRF-7 expression directly, rather than to select for a cell population with a high level of IRF-7. All of these data suggest that
LMP-1 is a factor necessary for the stimulation of the expres-
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FIG. 6. IFN-␣ can repress endogenous Qp activity in type I cells. (A) Repression of endogenous Qp by IFN-␣ in Eli-BL cells. Lanes 1 and 2, undigested
GAPDH and EBNA-1 probes, respectively; lanes 3 to 8, RNAs from Eli-BL
(lanes 3 to 5) or Rael (lanes 6 to 8) cells were used for RPA; lanes 3 and 6, mock
treatment; lanes 4 and 7, IFN-␣ treatment (500 U/ml, 48 h); lanes 5 and 8, IFN-␥
treatment (500 U/ml, 48 h). The reduction of EBNA-1 mRNA by IFN-␣ was
53%. Data were obtained by normalizing EBNA-1 levels to the GAPDH level
with the use of a PhosphorImager. One representative experiment of two independent experiments performed is shown. (B) IFN-␣ induces the expression of
IRF-7 in Eli-BL cells. Protein lysates from Rael (lanes 1 to 3) or Eli-BL (lanes
4 to 6) cells from the same experiment as shown in panel A were separated by
SDS-PAGE (8% gel) and stained with Ponceau S red after transfer of protein to
the membrane. Lanes 1 and 4, mock treatment; lanes 2 and 5, IFN-␣ treatment;
lanes 3 and 6, IFN-␥ treatment. Western blots with IRF-7 and ␥-tubulin antibodies were performed. (C) IFN-␣ induces ISG-15 expression in Rael cells.
Equal amounts of protein lysates from Rael with IFN-␣ treatment (lanes 2 and
3) or mock treatment (lane 1) were separated by SDS-PAGE (12% gel) and
stained with Ponceau S red after transfer of protein to the membrane. Western
blotting with ISG-15 antibody was performed. ns, nonspecific band.
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sion of IRF-7 in EBV-infected cells but not sufficient, as in the
case of Akata cells. Akata cells may have a mutation(s) in the
signal transduction pathway of LMP-1.
The fact that LMP-1 can stimulate the expression of IRF-7,
which is a negative regulator of Qp, predicts that LMP-1 may
be able to repress Qp through IRF-7. First, there is no LMP-1
expression in type I latency in which Qp is active; however,
LMP-1 expression in type III latency is associated with inactivation of Qp and induction of IRF-7. Second, LMP-1 could
repress the activity of Qp reporter constructs in DG75 cells and
reduce the endogenous EBNA-1 mRNA from Qp in a type I
cell line, Eli-BL (Fig. 4 and 5). In both cell lines, IRF-7 could
be induced by LMP-1 (Fig. 3 and 5). Third, overexpression of
IRF-7 could repress the activity of Qp reporter construct to an
extent similar to that exhibited by LMP-1 (Fig. 4B) and marginally reduce the endogenous EBNA-1 mRNA derived from
Qp (data not shown). Fourth, in Akata cells LMP-1 could not
induce the expression of IRF-7, and LMP-1 failed to repress
activity of a Qp reporter construct and to reduce the endogenous EBNA-1 mRNA (Fig. 4B and 5). Fifth, mutations in the
ISRE of Qp abolished the repression by LMP-1 or IRF-7 (Fig.
4C). Also, EBNA-2 could not stimulate the expression of
IRF-7 in DG75 cells and did not repress Qp activity (Fig. 2 to
4). These data strongly suggest that LMP-1 is a negative regulator of Qp and that the repression may be mediated by IRF-7
through the Qp ISRE. However, since in IRF-7A-transfected
cells the average EBNA-1 mRNA level (and standard deviation) relative to pcDNA3-transfected cells from five experiments was 0.68 ⫾ 0.15 (data not shown), an additional factor(s)
may cooperate with IRF-7 to repress Qp efficiently (68).
Interestingly, in type II latency, LMP-1 expression and an
active Qp can coexist (for a review, see reference 43). One
possible explanation is that LMP-1 in type II cells cannot
induce IRF-7 and thus fails to repress Qp. Preliminary results
suggest that this scenario may be correct (data not shown and
reference 68). More work is needed to address the relations
among LMP-1, IRF-7, and Qp activity in type II latency cells.
It is apparent that Qp activity is a balanced outcome of
positive and negative regulators, with IRFs strongly implicated
in its regulation. In type III latency, Qp may be turned off by a
combination of LMP-1, IRF-7, IRF-2, and higher levels of
EBNA-1 (9, 18, 51, 67, 68). The contribution of each repressor
to the inactivation of Qp in type III latency needs to be addressed further. In contrast, in type I latency when Qp is active,
low levels or absence of these negative factors plus some unidentified positive regulator(s) presumably cause the activation
of Qp. IRF-2 has been proposed as a primary activator of Qp
(39, 49), but that conclusion is disputed (68), and the identity
of the ISRE-mediated activator(s) is still uncertain.
Finally, IFN-␣, but not IFN-␥, has been shown to induce the
expression of IRF-7 (Fig. 6B; references 4, 32, and 39). As
expected, IFN-␣, but not IFN-␥, could repress endogenous Qp
activity in type I cells (Fig. 6A). The repression seems to be
associated with the ability of IFN to induce IRF-7 as exemplified by Eli-BL cells. In contrast, Qp activity in Rael cells, in
which IRF-7 could not be induced by IFN-␣, was not repressed
by IFN-␣ (Fig. 6A). Thus, the data overwhelmingly support the
idea that IRF-7 is a mediator of Qp repression. Also, it is
interesting that primary EBV infection could apparently induce IFN-␣ (26) and that proliferation of type III latency cells
is resistant to IFN (3, 24). These observations together with the
data reported here and in a previous report (67) suggest that
IFN-␣ by induction of IRF-7 silences Qp and favors usage of
C/Wp and facilitates expression of the EBV oncoproteins. This
scenario could function in primary infection.
LMP-1 is essential for the viral transformation process. In-
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terestingly, some IRFs have oncogenic capability (21, 23, 38).
Since the cellular function (especially oncogenic potential) of
IRF-7 is unknown, it is premature to speculate on the relation
between the induction of IRF-7 by LMP-1 and the transformation process in B cells. Whether IRF-7 is involved in the
pathogenesis of EBV-associated diseases and malignancies remains to be determined.
The present results expand the role of LMP-1 as a pleiotropic molecule in effecting deregulation of cellular genes. LMP-1
has been shown to induce numerous cellular genes with a
variety of functions. LMP-1 is now presented as a stimulator of
IRF-7 that, in turn, mediates the repression of the principal
type I latency promoter for EBNA-1, Qp, thus favoring the
switch to the use of type III latency promoters, C/Wp. The
complexity of regulation of EBV’s latency states is illustrated
by the fact that the principal product transcribed from C/Wp is
EBNA-2, which in turn amplifies the transcription of LMP-1.
Thus, both viral and IRF pathways may converge to determine
latency state.
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